ecopipam

structure given in first source

Also Known As:

6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(d)naphtho-(2,1b)azepine; Sch 39166; Sch-39166; Sch39166; 5H-Benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)-

Networked: 30 relevant articles (6 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - ecopipam: 30

Experts

1.	Chipkin, Richard: 3 articles (04/2016 - 08/2014)
2.	Brewer, Kori L: 2 articles (01/2020 - 01/2019)
3.	Budman, Cathy L: 2 articles (01/2018 - 01/2014)
4.	Chipkin, Richard E: 2 articles (01/2018 - 01/2014)
5.	Gilbert, Donald L: 2 articles (01/2018 - 01/2014)
6.	Grant, Jon E: 2 articles (01/2018 - 08/2014)
7.	Jinnah, H A: 2 articles (04/2016 - 01/2016)
8.	Khasnavis, Tanya: 2 articles (04/2016 - 01/2016)
9.	Sommerfeld, Barbara: 2 articles (04/2016 - 01/2016)
10.	Clemens, Stefan: 1 article (01/2020)

Related Diseases

1.	Tourette Syndrome (Tourette's Syndrome) 01/01/2023 - "Improvement in Clinical Global Impression of Tourette Syndrome Severity was also greater in the ecopipam group (P = .03). " 01/01/2018 - "We present results of a 4-week randomized, double-blind, placebo-controlled crossover study evaluating the safety, tolerability, and efficacy of the D1 receptor antagonist ecopipam in children and adolescents with Tourette syndrome. " 01/01/2023 - "This trial sought to further evaluate the efficacy, safety, and tolerability of ecopipam in children and adolescents with moderate to severe Tourette syndrome. " 01/01/2023 - "Ecopipam for Tourette Syndrome: A Randomized Trial." 01/01/2018 - "This placebo-controlled study of ecopipam supports further clinical trials in children and adolescents with Tourette syndrome. "
2.	Schizophrenia (Dementia Praecox) 10/01/1995 - "In the present open study the effects of the D1-dopamine antagonist SCH 39166 on positive and negative symptoms of schizophrenia (DSM-IIIR) were investigated. " 10/01/1995 - "SCH 39166 is the first selective D1-dopamine receptor antagonist developed for clinical trials in schizophrenia. " 12/01/1991 - "SCH 39166 [(-)-trans-6,7,7a,8,9, 13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo-[d]naphtho[2, 1b]azepine] has recently been described as a selective D1 antagonist and has entered clinical trials for the treatment of schizophrenia. " 03/01/1998 - "A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia." 10/01/1995 - "Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia."
3.	Weight Loss (Weight Reduction) 07/01/2007 - "Ecopipam was effective for achieving and maintaining weight loss in obese subjects, including type 2 diabetic subjects; however, the adverse effects on mood observed in the Phase 3 studies exclude its projected use in weight management." 07/01/2007 - "More subjects administered ecopipam vs. placebo achieved a 5% to 10% or >10% weight loss in two non-diabetic phase 3 trials. " 07/01/2007 - "In the Phase 3 studies, ecopipam 100 mg produced a 3.1% to 4.3% greater weight loss than placebo at 52 weeks. " 07/01/2007 - "In the Phase 2 study, 26% of subjects administered ecopipam 100 mg vs. 6% of placebo subjects achieved>or=5% weight loss after 12 weeks (p<0.01). " 07/01/2007 - "Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects."
4.	Gambling (Pathological Gambling) 08/01/2014 - "Ecopipam may offer promise for treating gambling disorder because of its antagonism of dopamine-1 receptors. " 08/01/2014 - "Twenty-eight individuals with gambling disorder were enrolled and received ≥1 dose of oral ecopipam in an 8-week trial (1 week placebo lead-in, 6 weeks of medication (50 to 100 mg/d as needed), and 1 week follow-up. " 08/01/2014 - "A single-blind study of 'as-needed' ecopipam for gambling disorder."
5.	Stuttering (Stammering) 01/01/2019 - "These positive, preliminary findings suggest that a doubleblind, randomized controlled clinical trial to examine the efficacy of ecopipam in the treatment of stuttering is warranted." 01/01/2019 - "Ecopipam as a pharmacologic treatment of stuttering."

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Dopamine D1 Receptors (Dopamine D1 Receptor)
3.	Dopamine (Intropin)
4.	Cocaine (Cocaine HCl)
5.	ecopipam
6.	SK&F 77434
7.	Morphine (MS Contin)
8.	Pramipexole (Mirapex)
9.	Dopamine D3 Receptors
10.	Raclopride

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Drug Therapy (Chemotherapy)